1	Researching COVID to enhance recovery (RECOVER) pregnancy study:
2	Rationale, objectives and design
3	Short Title: RECOVER Pregnancy Cohort Protocol
4	
5	Torri D. Metz <sup>1</sup> *; Rebecca G. Clifton²; Richard Gallagher³; Rachel S. Gross <sup>4</sup> ; Leora I. Horwitz <sup>5</sup> ;
6	Vanessa L. Jacoby <sup>6</sup> ; Susanne P. Martin-Herz <sup>7</sup> ; Myriam Peralta-Carcelen <sup>8</sup> ;Harrison T. Reeder <sup>9</sup> ;
7	Carmen J. Beamon <sup>10</sup> ; Marie-Abele Bind <sup>9</sup> ; James Chan <sup>9</sup> ; A. Ann Chang <sup>11</sup> ; Lori B. Chibnik <sup>9</sup> ;
8	Maged M. Costantine <sup>12</sup> ; Megan L. Fitzgerald <sup>5</sup> ; Andrea S. Foulkes <sup>9</sup> ; Kelly S. Gibson <sup>13</sup> ; Nick
9	Güthe <sup>5</sup> ; Mounira Habli <sup>14</sup> ; David N. Hackney <sup>15</sup> ; Matthew K. Hoffman <sup>16</sup> ; M. Camille Hoffman <sup>17</sup> ;
10	Brenna L. Hughes <sup>18</sup> ; Stuart D. Katz <sup>19</sup> ; Victoria Laleau <sup>20</sup> ; Gail Mallett <sup>21</sup> ; Hector Mendez-
11	Figueroa <sup>22</sup> ; Vanessa Monzon <sup>6</sup> ; Anna Palatnik <sup>23</sup> ; Kristy T.S. Palomares <sup>24</sup> ; Samuel Parry <sup>25</sup> ;
12	Myriam Peralta-Carcelen <sup>8</sup> ; Christian M. Pettker <sup>26</sup> ; Beth A. Plunkett <sup>27</sup> ; Athena Poppas <sup>28</sup> ; Uma M.
13	Reddy <sup>29</sup> ; Dwight J. Rouse <sup>30</sup> ; George R. Saade <sup>31</sup> ; Grecio J. Sandoval <sup>32</sup> ; Shannon M. Schlater <sup>33</sup> ;
14	Frank C. Sciurba <sup>34</sup> , Hyagriv N. Simhan <sup>35</sup> ; Daniel W. Skupski <sup>36</sup> ; Amber Sowles <sup>1</sup> ; Tanayott
15	Thaweethai <sup>9</sup> ; Gelise L. Thomas <sup>37</sup> ; John M. Thorp, Jr. <sup>38</sup> ; Alan T. Tita <sup>39</sup> ; Steven J. Weiner <sup>2</sup> ;
16	Samantha Weigand <sup>40</sup> ; Lynn M. Yee <sup>21</sup> ; Valerie J. Flaherman <sup>20</sup> on behalf of the RECOVER
17	Initiative^
18	
19	Affiliations:
20	<sup>1</sup> Department of Obstetrics and Gynecology, University of Utah Health Hospitals and Clinics, Salt
21	Lake City, UT, USA.
22	<sup>2</sup> Biostatistics Center, The George Washington University, Washington, DC, USA.
23	<sup>3</sup> Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New

1

York, NY, USA.

- <sup>4</sup>Department of Pediatrics, New York University Grossman School of Medicine, New York, NY,
- 26 USA.
- <sup>5</sup>Department of Population Health, New York University Grossman School of Medicine, New
- 28 York, NY, USA.
- <sup>6</sup>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California,
- 30 San Francisco, San Francisco, CA, USA.
- <sup>31</sup> <sup>7</sup>Department of Pediatrics, Division of Developmental Medicine, University of California San
- 32 Francisco, San Francisco, CA, San Francisco, CA, USA.
- <sup>8</sup>Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
- <sup>9</sup>Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA.
- <sup>10</sup>Department of Maternal Fetal Medicine, WakeMed Health and Hospitals, Raleigh, NC, USA.
- <sup>11</sup>Women's Health Research Clinical Center, University of California San Francisco, San
- 37 Francisco, CA, USA.
- <sup>12</sup>Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center,
- 39 Columbus, OH, USA.
- <sup>13</sup>Department of Obstetrics and Gynecology, The MetroHealth System, Cleveland, OH, USA.
- 41 <sup>14</sup>Division Maternal Fetal Medicine, Trihealth Good Samaritan Hospital Maternal Fetal Medicine,
- 42 Cincinnati, OH, USA.
- 43 <sup>15</sup>Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center: UH
- 44 Cleveland Medical Center, Cleveland, OH, USA.
- <sup>16</sup>Department of Obstetrics and Gynecology, Christiana Care Health System, Newark, DE, USA.
- 46 <sup>17</sup>Department of Obstetrics & Gynecology, University of Colorado School of Medicine, Aurora,
- 47 CO, USA.
- <sup>18</sup>Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.
- <sup>19</sup>Department of Medicine, New York University School of Medicine, New York City, NY, USA.

- <sup>20</sup>Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
- 51 <sup>21</sup>Department of Obstetrics and Gynecology, Northwestern University Feinberg School of
- 52 Medicine, Chicago, IL, USA.
- 53 <sup>22</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas
- 54 McGovern Medical School: The University of Texas Health Science Center at Houston John P
- and Katherine G McGovern Medical School, Houston, TX, USA.
- <sup>23</sup>Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI,
- 57 USA.
- <sup>24</sup>Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Saint Peter's
- 59 University Hospital, New Brunswick, NJ, USA.
- <sup>25</sup>Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.
- 61 <sup>26</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of
- 62 Medicine, New Haven, CT, USA.
- 63 <sup>27</sup>Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston,
- 64 IL, USA.
- <sup>28</sup>Division of Cardiology, Brown University Warren Alpert Medical School, PROVIDENCE, RI,
- 66 USA.
- <sup>29</sup>Department of Obstetrics and Gynecology, Columbia University, New York City, NY, USA.
- <sup>30</sup>Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA.
- <sup>31</sup>Department of Obstetrics and Gynecology, The University of Texas Medical Branch at
- 70 Galveston, Galveston, TX, USA.
- <sup>32</sup>Biostatistics Center, The George Washington University, Rockville, MD, USA.
- <sup>33</sup>Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
- <sup>34</sup>Department of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, University
- 74 of Pittsburgh, pittsburgh, PA, USA.

- <sup>35</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh
- 76 School of Medicine, Pittsburgh, PA, USA.
- <sup>36</sup>Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
- 78 <sup>37</sup>Clinical and Translational Science Collaborative of Cleveland, Case Western Reserve
- 79 University, Cleveland, Ohio, Cleveland, OH, USA.
- <sup>38</sup>Department of Obstetrics and Gynecology, UNC: The University of North Carolina at Chapel
- 81 Hill, Chapel Hill, NC, USA.
- <sup>39</sup>Department of Obstetrics and Gynecology, Center for Women's Reproductive Health,
- 83 University of Alabama at Birmingham, Birmingham, AL, USA.
- <sup>40</sup>Department of Obstetrics and Gynecology, Wright State University Boonshoft School of
- 85 Medicine, Dayton, OH, USA.
- 86
- 87 \* Corresponding author
- 88 Email: torri.metz@hsc.utah.edu (TM)
- <sup>89</sup> <sup>^</sup>Membership of the RECOVER Initiative is provided in the Acknowledgements.
- 90 Authorship has been determined according to ICMJE recommendations.
- 91 **Clinical Trials.gov Identifier:** Clinical Trial Registration: http://www.clinicaltrials.gov.
- 92 Unique identifier: NCT05172011

## 93 **Disclaimer**

- 94 The content is solely the responsibility of the authors and does not necessarily represent the
- 95 official views of the RECOVER program, the NIH or other funders.

## 96 Funding

97 This research was funded by the National Institutes of Health (NIH) Agreement OTA 98 OT2HL161841, OT2HL161847, and OT2HL156812 as part of the Researching COVID to 99 Enhance Recovery (RECOVER) research Initiative. This content is solely the responsibility of 100 the authors and does not necessarily represent the official views of the RECOVER Program or 101 the NIH.

## 102 Competing interests

103 Dr. Metz reports personal fees from Pfizer for her role as a medical consultant for a 104 SARS-CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for SARS-105 CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for RSV 106 vaccination in pregnancy study, and grants from Gestvision for role as a site PI for a 107 preeclampsia study outside the submitted work. Dr. Horwitz reported serving as a member of 108 the National Academy of Medicine Committee on the Long-Term Health Effects Stemming from 109 COVID-19 and Implications for the Social Security Administration. Dr. Costantine reported 110 receiving grant support for work not related to this paper from Baxter International and Siemens 111 Healthcare and personal consulting fees not related to this paper from Progenity and Siemens 112 Healthcare. 113 The other authors state that they have nothing to disclose.

# 115 Abstract

116	Importance: Pregnancy induces unique physiologic changes to the immune response
117	and hormonal changes leading to plausible differences in the risk of developing post-acute
118	sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy
119	may also have long-term ramifications for exposed offspring, and it is critical to evaluate the
120	health outcomes of exposed children. The National Institutes of Health (NIH) Researching
121	COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to
122	evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER-
123	Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.
124	Methods: RECOVER-Pregnancy cohort is a combined prospective and retrospective
125	cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19
126	pandemic and their offspring exposed and unexposed in utero, including single and multiple
127	gestations. Enrollment will occur both in person at 27 sites through the Eunice Kennedy Shriver
128	National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through
129	national recruitment by the study team at the University of California San Francisco (UCSF).
130	Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in
131	the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated
132	screening tools, laboratory analyses and symptom questionnaires followed by more in-depth
133	phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in
134	utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and
135	other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be
136	collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later
137	analyses proposed by RECOVER and other investigators.

- 138 **Discussion:** RECOVER-Pregnancy will address whether having SARS-CoV-2 during
- 139 pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort
- 140 will also establish whether there are increased risks of adverse long-term outcomes among
- 141 children exposed in utero.
- 142 **Registration:** NCT05172024

## 144 Introduction

The disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), results in both short-term and long-term sequelae, and many people with COVID-19 experience persistent health effects for months beyond initial infection.<sup>1-4</sup> Thus, evidence regarding the post-acute sequelae of SARS-CoV-2 (PASC) or "long COVID" is urgently needed to guide clinical care and inform public health policy.

Pregnant individuals may experience different long-term effects from COVID-19 than non-pregnant individuals due to the immunomodulatory effects of pregnancy. In a publication from the PRIORITY study consisting of pregnant individuals infected in 2020, 25% with COVID-19 experienced prolonged viral symptoms 8 weeks after infection, with median time to resolution of initial infection of 37 days.<sup>5</sup> Data beyond those first 8 weeks are not available. Thus, it remains unknown if there is a differential likelihood of PASC among individuals who contract SARS-CoV-2 during pregnancy compared with non-pregnant adults.

158 In addition, the offspring of patients with COVID-19 during pregnancy may be at 159 increased risk of both short and long-term morbidity related to in utero exposure to SARS-CoV-160 2, resulting from inflammation and vascular changes in the placenta<sup>6</sup>, as evidenced by 161 investigation of the effects of other viruses and in the setting of placental insufficiency. The 162 effects of SARS-CoV-2 on the health of pregnant individuals and their offspring may vary based 163 on SARS-CoV-2 variant, gestational age at infection, and maternal health and vaccination 164 status.<sup>7-12</sup> Existing data demonstrate that the Delta variant results both in the highest risk of 165 maternal critical illness and stillbirth, and in the most profound placental effects.<sup>7,8</sup> Vaccination 166 has been found to be protective against both severe maternal COVID-19 and adverse 167 pregnancy outcomes, and may also influence the incidence of PASC in this population.<sup>9-11</sup>

168 The National Institute of Health's (NIH) RECOVER initiative has a unique opportunity to 169 study the post-acute sequelae of SARS-CoV-2 acquired in pregnancy. RECOVER-Pregnancy 170 will enroll maternal-child dyads to investigate the effects of SARS-CoV-2 acquired during 171 pregnancy on the long-term health of both the pregnant person and their offspring who were 172 exposed to SARS-CoV-2 in utero. We hypothesize that the incidence of persistent long-term 173 sequelae among pregnant people will vary from that of non-pregnant adults given the unique 174 changes in physiology, hormone levels, and inflammatory milieu in pregnancy. In addition, we 175 hypothesize that the offspring of individuals with SARS-CoV-2 infection in pregnancy will have 176 worse developmental outcomes when compared with unexposed offspring delivered over the 177 same time period. The overarching goal of RECOVER-Pregnancy is to describe PASC in 178 people who are infected with SARS-CoV-2 in pregnancy and examine the outcomes of their 179 offspring compared with children who were not exposed to SARS-CoV-2 in utero.

## **180** Materials and Methods

#### 181 **Objectives**

182 RECOVER-Pregnancy cohort will enroll maternal-child dyads exposed and unexposed
 183 to SARS-CoV-2 during pregnancy, with pregnant individuals participating in RECOVER-Adult
 184 and offspring participating as the in utero exposed subgroup of RECOVER-Pediatric.
 185 The broad objectives of both the RECOVER-Adult and RECOVER-Pediatric studies are
 186 to: (1) characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection; (2)
 187 characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history,
 188 and distinct phenotypes identified as sequelae of SARS-CoV-2 infection; (3) identify

demographic, social, and clinical risk factors for PASC and PASC recovery, and (4) define the
biological mechanisms underlying pathogenesis of PASC.

191 The study protocols for both RECOVER-Adult and RECOVER-Pediatric cohorts are 192 published separately.<sup>13,14</sup> The RECOVER-Pregnancy cohort is summarized here. The primary 193 aims of the adult portion of the RECOVER-Pregnancy cohort include: (1) describing PASC 194 onset, symptoms and severity by comparing pregnant individuals with SARS-CoV-2 with 195 pregnant individuals without SARS-CoV-2, (2) characterizing risk factors for PASC onset, 196 symptoms and severity following SARS-CoV-2 infection during pregnancy by comparing 197 infected pregnant individuals with and without particular risk factors; and (3) evaluating if 198 contracting SARS-CoV-2 in pregnancy is associated with a differential risk of developing PASC 199 compared with non-pregnant individuals. The primary aims of the pediatric portion of the 200 RECOVER-Pregnancy cohort include characterizing the clinical manifestations of exposure to 201 SARS-CoV-2 infection during pregnancy on child physical health and behavioral and 202 developmental outcomes, by comparing children with and without maternal history of SARS-203 CoV-2 infection during pregnancy.

#### 204 Study design and setting

205 The NIH RECOVER study is a retrospective and prospective longitudinal meta-cohort 206 study design in which individuals with and without exposure to SARS-CoV-2 infection are 207 enrolled and followed over a maximum of 4 years. For RECOVER-Pregnancy, individuals with 208 and without SARS-CoV-2 infection during pregnancy will be included. Individuals with a SARS-209 CoV-2 infection during pregnancy will be further classified as acute (infection within the past 30 210 days at the time of enrollment) and post-acute (more than 30 days since infection). The 211 RECOVER-Pregnancy cohort follows both the adult protocol and the part of the pediatric 212 protocol that is specific to in utero exposure to SARS-CoV-2.

213 Mother-child dyads for the RECOVER-Pregnancy cohort are recruited in person at 12 214 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 215 Maternal-Fetal Medicine Units (MFMU) Network Centers which include 26 individual hospital 216 sites (encompassing community and academic hospitals) and remotely nationwide by the 217 University of California San Francisco (UCSF). A list of study sites can be obtained at 218 https://recovercovid.org or in Appendix 1. For participants recruited within the 26 individual 219 hospital sites of the MFMU Network, recruitment occurs among individuals who were enrolled in 220 the NICHD MFMU Gestational Research Assessments for COVID-19 (GRAVID) study<sup>15,16</sup>, a 221 previously established cohort of individuals with and without SARS-CoV-2 during pregnancy 222 over the COVID-19 pandemic, and new prospective enrollments of individuals with and without 223 SARS-CoV-2 in pregnancy to encompass all variants of SARS-CoV-2. Study procedures for 224 participants recruited by NICHD MFMU Network sites will be completed through a combination 225 of remote survey assessments and in-person study visits. For those recruited remotely by the 226 study team at the UCSF, recruitment occurs among individuals who were enrolled in the 227 PRIORITY study, a previously established nationwide cohort of individuals with SARS-CoV-2 228 during pregnancy, as well as through new nationwide outreach including social media outreach, 229 referrals from the NIH RECOVER website, screening of the UCSF electronic health record and 230 from RECOVER-Adult cohort sites that are not also participating in the pregnancy cohort. 231 Participants recruited by UCSF will have study procedures such as anthropometric 232 measurements and specimen collections completed during home visits while surveys are 233 completed remotely. Individuals who are able to travel to UCSF may have study procedures 234 completed in person. Participants can only be enrolled once to avoid overlap in recruitment 235 across the RECOVER-Pregnancy sites.

#### 236 Study population

237 Anyone with SARS-CoV-2 infection during pregnancy (defined as meeting World Health 238 Organization criteria<sup>17</sup> for suspected, probable or confirmed SARS-CoV-2 infection), or with 239 documented lack of SARS-CoV-2 exposure during pregnancy, irrespective of pregnancy 240 outcome (loss, termination, or live birth) is eligible to enroll in RECOVER-Pregnancy (See 241 RECOVER-Adult protocol for detailed definition).<sup>13</sup> The index date for infection is set as the date 242 of the first infection as determined by the date of a positive SARS-CoV-2 test, or set at 90 days 243 prior to antibody test date for those with positive antibodies who had an asymptomatic prior 244 infection. Individuals with SARS-CoV-2 in pregnancies resulting in a live birth are only eligible 245 for enrollment into one of the RECOVER pregnancy cohorts to facilitate co-enrollment of the 246 offspring in the in utero exposure part of the pediatric protocol. Individuals with pregnancies 247 resulting in pregnancy loss or termination are eligible to enroll at any adult cohort site. 248 Pregnancies and pregnancy outcomes for all adults in the RECOVER-Adult cohort over the 249 longitudinal follow-up period for RECOVER will also be recorded.

Those who had a pregnancy during the study enrollment window without SARS-CoV-2 250 251 infection are eligible for enrollment as uninfected controls. Uninfected controls must have no 252 reported history of SARS-CoV-2 infection, and be PCR negative and SARS-CoV-2 antibody 253 negative at the time of enrollment. For the pregnancy cohort, index date for the post-acute 254 uninfected controls is set at the date of delivery as the uninfected period of interest is the 255 pregnancy (e.g. controls should not have been infected during pregnancy). The recruitment 256 strategy seeks to have infected and uninfected individuals enrolled within the same time frame 257 to reduce potential effects of societal modifications during the pandemic which may also affect 258 neurodevelopment (e.g., social isolation, disruptions to education and childcare services, 259 financial parental stressors, etc).18, 19

#### 260 Sample size

261 Overall 2,300 adults with or without SARS-CoV-2 during pregnancy will be enrolled in 262 RECOVER-Pregnancy along with their offspring. Of the 2300 pregnant individuals enrolled in 263 the adult cohort, we plan to enroll 1867 infected with SARS-CoV-2 during pregnancy and 433 264 uninfected during pregnancy. Because pregnant participants are enrolling as dyads with their 265 offspring, we expect to enroll corresponding numbers of offspring exposed to SARS-CoV-2 266 during pregnancy and unexposed during pregnancy, allowing for variability due to factors such 267 as twins or multiple gestations and pregnancy loss. Of the adults enrolling in RECOVER-268 Pregnancy with SARS-CoV-2 infections, we plan for 15% of them to be enrolled during a period 269 of acute infection (within 30 days of positive SARS-CoV-2 test). 270 For each comparison underlying the primary study objectives, we computed minimum 271 effect sizes detectable with 90% power and a type-1 error rate of 0.01, for the full target sample 272 sizes, as well as for only 25% of the overall cohort, as would be expected in a subgroup 273 analysis. These results are also reported in Table 1. The minimum detectable PASC risk 274 difference between pregnant participants with and without infection is 8.4% (15.8% in a 25% 275 subgroup), assuming the risk of developing PASC among participants with infection is 25%. 276 Assuming the prevalence of a given risk factor among pregnant participants with infection is 277 20%, and the risk of PASC in pregnant participants with infection who have the risk factor is 278 30%, the minimum detectable PASC risk difference between infected participants with and 279 without the risk factor is 9.5% (17.4% in a 25% subgroup). Assuming 25% of non-pregnant adult 280 participants are female and of reproductive age, the minimum detectable PASC risk difference 281 between SARS-CoV-2 infected participants with and without active pregnancy at infection is 282 4.7% (8.9% in a 25% subgroup). Finally, the minimum detectable difference in a continuous

- biomarker or development score between offspring exposed to SARS-CoV-2 in utero and those
- unexposed during pregnancy is 0.206 standard deviations (0.413 in a 25% subgroup).
- Table 1. Sample size calculations for RECOVER-Pregnancy cohort (ES: effect size; RF: risk
- 286 factor; RF+: risk factor positive; SD: standard deviation)

Comparison gro	oups	Effect of	Assumptions	Min. Detectable		
		interest		ES		
				(90% power, 0.01		
				type I error rate)		
				Full 25%		
				Sampl	Subgrou	
				е	р	
Pregnant	Pregnant	Difference in	Risk of PASC in	8.4%	15.8%	
infected	uninfected	risk of PASC	infected: 25%			
(n=1867)	(n=433)					
Pregnant	Pregnant	Difference in	Prevalence of RF:	9.5%	17.4%	
infected w/	infected w/out	risk of PASC	20%			
RF	RF (n=1494)		Risk of PASC in			
(n=373)			infected, RF+:			
			30%			
Pregnant Non-pregnant		Difference in	Risk of PASC in 4.7%		8.9%	
infected	infected	risk of PASC	non-pregnant			
(n=1867)	reproductive		infected: 25%			

	age female		25% of non-		
	(n=3283)		pregnant infected		
			are reproductive		
			age females		
Infant	Infant not	Difference in	Equal variances	0.206	0.413
exposed in-	exposed in-	continuous		SDs	SDs
utero	utero	biomarker or			
(n=1867)	(n=433)	development			
		score			

287

288 Importantly, adult RECOVER-Pregnancy cohort participants will be included in the 289 planned primary analyses for RECOVER-Adult. Classification of adult pregnancy cohort 290 participants will vary depending on the analysis being performed. For example, an adult 291 participant who was uninfected during pregnancy will remain in the uninfected comparison 292 group for all analyses examining outcomes of the offspring, as the offspring will not be exposed 293 in utero. However, some of the enrolled adult pregnancy participants who were enrolled as 294 uninfected controls will acquire SARS-CoV-2 infection during the 4-year longitudinal follow-up 295 period. These participants will cross over to the infected group for the adult cohort, and will be 296 analyzed as infected in analyses assessing only the adult outcomes from that time period 297 forward, but their offspring will remain in the unexposed pediatric cohort. Thus, the RECOVER 298 Data Resource Center (DRC) will classify pregnant individuals with SARS-CoV-2 and their 299 offspring intentionally and separately for each analysis depending on the outcome being 300 examined.

#### 301 Study procedures

302	Details of protocol development are included separately in study protocol manuscripts
303	for the RECOVER-Adult and RECOVER-Pediatric protocols. <sup>13,14</sup> Development of the pregnancy
304	cohort study procedures and protocol occurred concurrently with the principal investigators for
305	the pregnancy cohort participating in the development of both the RECOVER-Adult and
306	RECOVER-Pediatric protocols. Study procedures for RECOVER-Adult are included in Figure 1.
307	Figure 1. Study procedures for RECOVER-Adult
308	A schematic of the relationship between pregnant individuals and their offspring, and the
309	distribution of acute and post-acute SARS-CoV-2 infection is included in Figure 2. For adult
310	participants, the pregnant cohort simply represents a predefined portion of the participants to
311	ensure that PASC following SARS-CoV-2 infection during pregnancy can be examined and to
312	examine differential effects when SARS-CoV-2 is acquired during pregnancy.
313	Figure 2. Schematic representation of planned enrollment for RECOVER-Pregnancy
314	including pregnant individuals (both with and without SARS-CoV-2 during pregnancy) and the
315	pediatric in utero exposure cohort. Acute infection is infection within the last 30 days and post-
316	acute infection is infection during pregnancy, but at a time that was more than 30 days from the
317	date of enrollment.

### 318 Adult cohort

The primary endpoint for the adult portion of the RECOVER-Pregnancy cohort mirrors that of the larger adult cohort and is defined as the presence of incident or prevalent candidate PASC symptoms over time. Secondary endpoints include biological and recovery trajectories from SARS-CoV-2 infection, documentation of organ injury, and incident clinical diagnoses.

323 Tier 1 RECOVER adult study procedures consist of completion of symptom surveys for a 324 variety of PASC symptoms, height, weight and vital signs measurements, sit to stand and active 325 stand evaluations, a core set of laboratory studies, and biospecimen collection. Each Tier 2 test 326 is expected to be completed by approximately 30% of adult participants. Tier 2 testing can be 327 triggered by abnormal values or responses in Tier 1; in addition, tier 2 testing is triggered in a 328 randomly selected group of controls for comparison. Adult Tier 3 tests are both more invasive 329 and more time consuming. Each tier 3 test is expected to be performed in approximately 20% of 330 RECOVER participants. Participants may select to opt out of tier 2 and tier 3 tests without 331 withdrawing from the study.

332 Adult participants in the pregnancy cohort complete all of the Tier 1 study procedures as 333 defined in the adult cohort study design manuscript.<sup>13</sup> Similarly, pregnancy cohort participants 334 are eligible for all of the Tier 2 and 3 study procedures with the exception of those detailed in 335 Table 2 as these were felt to have unacceptable risk to the participant, the fetus, or neonate for 336 this observational study. Similarly, triggers for some of the Tier 2 and Tier 3 tests have been 337 modified for those who are pregnant, postpartum (within 3 months of delivery date), or 338 breastfeeding as they would not be appropriate triggers during these time periods (Table 2). For 339 example, weight loss is not used as a test trigger for participants who are postpartum as weight 340 loss is anticipated postpartum.

341 Table 2. RECOVER-Adult study procedure modifications for pregnant, breastfeeding, or

342 postpartum individuals

Tier of	Adult Study	Excluded Population	Justification for Modification
Test	Procedure		
	Modification		

Tier 2	Volumetric non-	Pregnant and <3 months	Unacceptable risk of radiation
	contrast chest CT	postpartum	exposure to the fetus without
			direct benefit
Tier 2	Dual energy chest	Pregnant and <3 months	Unacceptable risk of radiation
	CT with contrast	postpartum	exposure to the fetus without
			direct benefit
Tier 3	MRI brain with	Pregnant and <3 months	Unacceptable risk of gadolinium
	gadolinium	postpartum	exposure for fetus and neonate
			(via breastmilk) with no direct
			participant benefit
Tier 3	Cardiac imaging with	Pregnant and <3 months	Unacceptable risk of mIBG
	meta-	postpartum	exposure for fetus and neonate
	iodobenzylguanidine		(via breastmilk) with no direct
	(mIBG)		participant benefit
Tier 3	Gastric emptying	Pregnant and <3 months	Physiologic changes in
	study	postpartum	pregnancy and early
			postpartum period with gut
			motility precludes accurate
			interpretation
Tier 3	Skin biopsy	Pregnant and <3 months	Invasive procedure without
		postpartum	direct participant benefit
Tier 3	Muscle biopsy	Pregnant and <3 months	Invasive procedure without
		postpartum	direct participant benefit

Tier 3	Lumbar puncture	Pregnant and <3 months	Invasive procedure without
		postpartum	direct participant benefit
Tier 3	Tilt table testing	Pregnant and <3 months	Physiologic changes in
		postpartum	pregnancy and early
			postpartum period with
			vasodilatory response
			precludes accurate
			interpretation
Tier 3	Full cardiopulmonary	Pregnant and postpartum	Exercise tolerance differs
	exercise testing		during pregnancy and early
			postpartum period which
			precludes accurate
			interpretation
Tier 3	Bronchoscopy	Pregnant and postpartum	Invasive procedure and
			anesthesia without direct
			participant benefit
Tier 3	Right heart	Pregnant and postpartum	Invasive procedure and
	catheterization		anesthesia without direct
			participant benefit
Tier 3	Upper endoscopy	Pregnant and postpartum	Invasive procedure and
			anesthesia without direct
			participant benefit

Tier 3	Colonoscopy with or	Pregnant and postpartum	Invasive procedure and
	without biopsy		anesthesia without direct
			participant benefit
Tier 3	Cardiac imaging with	Breastfeeding	Unacceptable risk of contrast
	meta-		exposure to neonate through
	iodobenzylguanidine		breastmilk with no direct
	(mIBG)		participant benefit
Tier 3	Gastric emptying	Breastfeeding	Unacceptable risk of contrast
	study		exposure to neonate through
			breastmilk with no direct
			participant benefit

343

344 Pregnancy characteristics and pregnancy outcome data will be ascertained by maternal

345 self-report through survey questions following the end of pregnancy. The survey questions will

346 be validated through manual medical record abstraction at the NICHD MFMU Centers as

347 medical record data for participants are readily available at the Centers. Pregnancy

348 characteristics and outcome data that will be collected are included in Box 1. Additional

349 important covariates that are being collected include trimester of pregnancy at time of infection,

350 severity of infection and treatment for infection.

Box 1. Pregnancy Outcome Data Ascertained for RECOVER-Pregnancy Cohort

Estimated date of delivery

Actual delivery date

Number of prior pregnancies and outcome of prior pregnancies

Number of fetuses in index pregnancy (either infected or uninfected with SARS-CoV-2)

Live birth, stillbirth, miscarriage, or termination Birthweight of fetus(es) Gestational diabetes Hypertensive disorder of pregnancy Cesarean birth Diagnosis of intraamniotic infection Placental abruption Administration of magnesium sulfate Administration of antenatal corticosteroids Postpartum hemorrhage ICU admission during delivery hospitalization

### 351 Pediatric in utero exposure cohort

352 All children will participate in Tier 1 assessments, which include broad health screening 353 measures collected remotely via electronic surveys or telephone interviews, and Tier 2 354 assessments, which include more in-depth clinical assessments conducted either at in-person 355 visits or via videoconferencing. Tier 1 assessments occur at 12, 18, 24, 36 and 48 months of 356 age, and Tier 2 assessments occur at 24, 36 and 48 months of age (Figure 3). 357 Figure 3. Study assessment schedule for children enrolled in RECOVER-Pregnancy or the in 358 utero exposure cohort of RECOVER 359 Both Tiers 1 and 2 focus primarily on child developmental outcomes. Tier 1 includes 360 developmental screening across the domains of communication, gross motor, fine motor, 361 problem solving, and personal-social development using the Ages and Stages Questionnaire-362 3<sup>rd</sup> Edition (ASQ-3)<sup>20-22</sup>, social-emotional screening using the Ages and Stages Questionnaires: 363 Social-Emotional, 2nd Edition (ASQ:SE-2) and standardized screening for Autism Spectrum 21

Disorder (ASD) using the Modified Checklist for Autism in Toddlers Revised with Follow up
(MCHAT-RF)<sup>23</sup> (Figure 3). Child socioemotional and behavioral status will be assessed using
the Child Behavior Checklist (CBCL)<sup>24</sup>. In addition, adaptive behavior, communication, cognitive
development, social emotional development, and physical development, will be assessed using
the Developmental Profile-4 (DP-4)<sup>25</sup> by direct caregiver interview (Figure 3).

369 Tier 2 assessments will include an evaluation of child development using the Bayley 370 Scales of Infant and Toddler Development, 4th Edition (Bayley-4)<sup>26</sup> and the Differential Abilities 371 Scales, 2<sup>nd</sup> Edition (DAS-II)<sup>27</sup>. The Bayley-4 is a comprehensive developmental assessment tool 372 which will evaluate cognitive, language, and motor development for RECOVER. The DAS-II is a 373 comprehensive assessment that provides insight into how a child processes information and 374 problem-solving, related to verbal comprehension and nonverbal and spatial reasoning. Training 375 for administration of the Bayley-4, DAS-II and DP-4 will be conducted centrally by the 376 RECOVER Clinical Science Core (CSC) Neurocognitive Leadership Team, and videos of mock 377 administrations will be reviewed for all examiners to ensure validity of the administered exam 378 prior to performing any exams for the purposes of the RECOVER study. 379 In addition to the neurocognitive outcomes, broader child health outcomes are assessed 380 as well. Tier 1 surveys assess sociodemographic information, medical history and special health

care needs using items from the National Surveys of Children's Health<sup>28</sup>, SARS-CoV-2 infection

history, related conditions (e.g., Multisystem inflammatory syndrome in children (MIS-C),

383 Postural Orthostatic Tachycardia Syndrome, and Long COVID diagnoses), COVID-19 testing

and vaccine history, COVID-19-related symptoms (acute and long-term), COVID-19 health

385 consequences (e.g., diet, physical activity, sleep, screen time, schooling, parenting) and social

determinants of health (e.g., early childhood experiences or stressors). Brief infant Sleep

387 Questionnaire (BISQ)<sup>29</sup> is also collected at 24 months of age.

388 Other Tier 2 assessments include anthropometric measurements, such as child weight, 389 length/height, and head circumference measured using well calibrated, quality instruments and 390 standardized techniques, to ultimately assess child weight trajectories, weight status and 391 cardiometabolic risk. A sample of blood will be obtained at 24 months for SARS-CoV-2 antibody 392 testing and central biobanking. Blood will be collected at 24 months by a trained and 393 experienced pediatric phlebotomist, or through remote at-home collection using a TASSO M20 394 device, which collects capillary blood using 4 volumetric sponges that each hold 17.5µL of blood 395 (70 µL total). If using the Tasso M20 device, one sponge is used for SARS-CoV-2 spike and 396 nucleocapsid antibody testing and remaining sponges are banked for future use. If using in-397 person phlebotomy, EDTA and SST tubes will be collected ensuring that the total blood volume 398 is less than 2 mL per kg of body weight.

#### 399 Data collection, management and quality assurance

All data are collected through secure entry into a single instance of REDCap created by the RECOVER DRC. Oversight of data and safety is provided by the RECOVER Observational Safety Monitoring Board (OSMB) appointed by the National Institutes of Health (NIH). The purpose of the OSMB is to assure independent review as to whether study patients are exposed to unreasonable risk because of study participation, and to monitor study progress and integrity. Data collection and quality assurance are further detailed in the RECOVER-Adult cohort study design manuscript.<sup>13</sup>

#### 407 **Statistical analysis**

The point prevalence of PASC symptoms, defined as the proportion of participants
reporting a symptom at a given follow-up time point among those remaining in RECOVER, will

be calculated across the follow-up period for participants with infection during pregnancy and
without infection during pregnancy, both overall and among those whose pregnancy has ended
(termination, miscarriage, or delivery). Odds ratios (ORs) adjusted for demographic factors will
be reported. A paradigm for identifying PASC cases will be developed in the broader adult
cohort as described in the RECOVER-Adult study design paper, and evaluated in the population
with SARS-CoV-2 infection during pregnancy along with alternative clinically-derived PASC
definitions.

Logistic regression analyses will be conducted to investigate associations between cumulative incidence of PASC and clinical factors, demographics, and social determinants of health among participants with infection during pregnancy, as well as comparing those infected during pregnancy with infected non-pregnant reproductive age females. Sensitivity analyses assessing the influence of pregnancy factors such as gestational age at infection, and timing of follow-up visits relative to the end of pregnancy, will be considered.

423 Measures of child physical health and behavioral and developmental outcomes will be 424 summarized in the in utero exposure to SARS-CoV-2 cohort overall and by maternal infection 425 status during pregnancy. Two-sample, two-sided t-tests will be used to compare cross-sectional 426 means of continuous outcomes between groups, and chi-squared tests will be used to compare 427 categorical outcomes between groups. Multivariable linear and generalized linear regression 428 models will also be fit to adjust for relevant baseline factors that are different between groups. 429 For outcomes measured at multiple visits, trajectories will be modeled and compared using 430 linear and generalized linear mixed effects models.

#### 431 Safety and possible risks

All RECOVER activities are approved by a single institutional review board (IRB), which
 is the New York University IRB. All of the RECOVER-Pregnancy sites will establish reliance on
 24

the single IRB for RECOVER. Any protocol modifications will be approved by the single IRB and
communicated with all RECOVER investigators and research staff by the CSC. Written informed
consent will be obtained for all participants by research personnel at participating RECOVERPregnancy sites. Participants will have the opportunity to opt out of storage of specimens for
future use and for genetic analyses.

439 For both the pediatric and adult cohort portions of the pregnancy cohort, results from 440 laboratory testing and other tests performed as study procedures are monitored centrally by the 441 CSC, DRC, and the individual site PIs along with their research teams. For each lab result, the 442 research team determines if the result is normal and abnormal, and if abnormal whether it is 443 clinically actionable. For pregnant participants, many of the laboratory results fall outside of 444 established lab normal values; yet, are normal for pregnant individuals. Thus, thresholds for 445 clinical action differ for this special population and the need for clinical action will be determined 446 by the investigators at each site who are obstetricians or maternal-fetal medicine subspecialists. 447 If the neurodevelopmental test score or social emotional score falls in a range where 448 additional monitoring or referral are recommended, results of screening tests completed in Tier 449 1 (ASQ-3, ASQ:SE-2, MCHAT R/F) or assessment tests completed in Tier 2 (Bayley-4, DAS-II 450 and DP-4) will be provided to the caregiver of the participant with a recommendation to follow-451 up with the child's primary health care provider. Ranges of concern will be determined by 452 psychologists and developmental-behavioral pediatricians, and standardized across the cohort.

### 453 **Discussion**

The NIH RECOVER-Pregnancy cohort will answer critical questions regarding the incidence and trajectory of PASC following SARS-CoV-2 infection during pregnancy, and the effects of in utero exposure to SARS-CoV-2 infection on offspring development. There are little

457 data regarding the incidence of PASC in a population who acquired SARS-CoV-2 during 458 pregnancy. Initial data from the PRIORITY Registry suggest persistence of symptoms among 459 pregnant individuals for weeks to months after SARS-CoV-2 infection.<sup>5</sup> As pregnant individuals 460 have alterations in inflammatory response and hormone levels, and have been noted to have an 461 increased risk of severe or critical illness with SARS-CoV-2 infection, it is plausible that the rates 462 of PASC could be different in this group.<sup>4,30,31</sup> Differences in the prevalence or symptoms of 463 PASC among those who acquire SARS-CoV-2 in pregnancy compared with non-pregnant 464 individuals could help with determination of the underlying pathophysiology of PASC.

465 Recent research suggests that being born during the pandemic is associated with lower 466 scores on neurodevelopmental screening than in historical controls; however, exposure to 467 SARS-CoV-2 infection alone was not associated with a difference from unexposed children 468 living through the pandemic.<sup>18,19</sup> A large administrative database study by Edlow and colleagues 469 found an association between exposure to SARS-CoV-2 in utero and neurodevelopmental 470 diagnoses, but was limited by the possibility of ascertainment bias, because those exposed to 471 SARS-CoV-2 may have been more likely to be followed and referred.<sup>32</sup> The RECOVER-472 Pregnancy study will add to this available evidence by comparing children who were SARS-473 CoV-2 exposed with contemporaneous unexposed controls, and following them longitudinally 474 over time. The RECOVER-Pregnancy study will also be able to examine for potential 475 differences in subsets of the population exposed to SARS-CoV-2 in utero, such as by trimester 476 of infection, or by maternal disease severity and treatments for SARS-CoV-2. 477 The design of the pregnancy cohort provides several strengths. Enrollment of maternal-

child dyads across the U.S. will increase generalizability of study results, enhance racial, ethnic,
and socioeconomic diversity, and enable collection of detailed information on both the mother
and the child to enable robust analyses. SARS-CoV-2 is known to have disproportionately
affected Black and Latino communities (especially early in the pandemic)<sup>33, 34</sup>; thus, the

482 RECOVER-Pregnancy investigators are committed to reaching a diverse population for studying 483 the long-term effects of contracting SARS-CoV-2 in pregnancy. Individuals with pregnancies 484 across the time period of the COVID-19 pandemic will be included allowing for comparisons by 485 major SARS-CoV-2 variants, which are known to differentially affect pregnancy outcomes.<sup>7,8</sup> 486 Allowing both in-person and remote assessments may help reach participants who could not 487 participate in one or the other types of study visits. Developmental and socioemotional-488 behavioral screening and direct neurodevelopmental assessments will be performed by 489 centrally trained and certified study personnel.

Our study design has several important limitations. First, since study procedures are extensive and require significant time, families who have less availability to attend study visits may be less likely to enroll in or more likely to be lost to follow up. This could reduce the generalizability of our results. In addition, because participants born at any time during the pandemic are eligible for enrollment, participants born earlier in the pandemic will not be able to be assessed for outcomes measured by the study at ages prior to their date of enrollment; thus, we will have smaller sample sizes available for some of the pediatric outcomes.

We anticipate that further modifications to the protocol will be made as the COVID-19 pandemic evolves and the scientific community learns more about both PASC and the effects of exposure to SARS-CoV-2 in utero on offspring. Nonetheless we have designed a rigorous study to evaluate the effect of SARS-CoV-2 on maternal-child dyads and anticipate that it will substantially further scientific understanding of the risks of contracting SARS-CoV-2 while pregnant.

# 503 Acknowledgements

We would like to thank the National Community Engagement Group (NCEG), all patient,
caregiver and community representatives, and all the participants enrolled in the RECOVER
initiative.
Membership of the RECOVER Initiative is provided in a supplemental appendix file.

## 508 Supporting Information

509 The supporting information is provided in a supplemental appendix file.

## 511 **References**

- Ballering AV, van Zon SKR, Hartman TCO, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet* 2022; 400: 452-61.
- Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.
   *JAMA* 2020; 324(6): 603-05.
- 517 3. Bull-Otterson L. Post-COVID conditions among adult COVID-19 survivors aged 18-64
   518 and ≥ 65 years old United States, March 2020-November 2021. *MMWR* 2021; 71:713.
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Reviews Microbiology* 2023; 21: 133-146.
- Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical presentation of coronavirus disease
   2019 (COVID-19) in pregnant and recently pregnant people. *Obstet Gynecol* 2020;
   136(6):1117-25.
- 524 6. Schwartz DA, Avvad-Portari E, Babal P, et al. Placental tissue destruction and
  525 insufficiency from COVID-19 causes stillbirth and neonatal death from hypoxic-ischemic
  526 injury: a study of 68 cases with SARS-CoV-2 placentitis from 12 countries. *Arch Pathol*527 *Lab Med* 2022; 146(6):660-76.
- Seasely AR, Blanchard CT, Arora N, et al. Maternal and Perinatal Outcomes Associated
   With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infection. *Obstet Gynecol* 2022;140(2):262-265.
- Adhikari EH, SoRelle JA, McIntire DD, Spong CY. Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge. *Am J Obstet Gynecol* 2022;226(1):149-151.
- 534
  535
  9. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. *Nat Med* 2022;28(3):504.
- 536 10. Hui L, Marzan MB, Rolnik DL, et al. Reductions in stillbirths and preterm birth in COVID 537 19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal
   538 outcomes. *Am J Obstet Gynecol* 2022; epub ahead of print.
- 11. Morgan JA, Biggio JR, Jr., Martin JK, et al. Maternal Outcomes After Severe Acute
   Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared
   With Unvaccinated Pregnant Patients. *Obstet Gynecol* 2022;139(1):107-109.
- 542 12. Hughes BL, Sandoval GJ, Metz TD, et al. First- or second-trimester SARS-CoV-2
  543 infection and subsequent pregnancy outcomes. *Am J Obstet Gynecol* 2022; epub
  544 ahead of print.
- 545 13. Horwitz L, et al. National Institutes of Health REsearching COVID to Enhance Recovery
   546 (RECOVER) Adult Cohort: Rationale, Objectives, and Study Design; submitted
   547 concurrently.

- 548 14. Gross R, et al. National Institutes of Health REsearching COVID to Enhance Recovery (RECOVER) Pediatric Cohort: Rationale, Objectives, and Study Design; submitted 550 concurrently.
- 15. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and
   Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association of
   SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality from Obstetric
   Complications. JAMA 2022; 327(8):748-59.
- 16. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and
  Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association
  Between Giving Birth During the Early Coronavirus Disease 2019 (COVID-19) Pandemic
  and Serious Maternal Morbidity. *Obstet Gynecol* 2023; 141(1):109-118.
- 55917. World Health Organization. WHO COVID-19: case definitions, updated in public health<br/>surveillance for COVID-19, 22 July 2022. <a href="https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance\_Case\_Definition-2022.1">https://www.who.int/publications/i/item/WHO-</a><br/>5615612019-nCoV-Surveillance\_Case\_Definition-2022.1Accessed March 9, 2023.
- 562 18. Shuffrey LC, Firestein MR, Kyle MH, et al. Association of Birth During the COVID-19
  563 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In
  564 Utero Exposure to Maternal SARS-CoV-2 Infection. JAMA Pediatr. Published online
  565 January 4, 2022:e215563. doi:10.1001/jamapediatrics.2021.5563
- 19. Huang P, Zhou F, Guo Y, et al. Association Between the COVID-19 Pandemic and
  Infant Neurodevelopment: A Comparison Before and During COVID-19. *Front Pediatr.*2021;9:662165. doi:10.3389/fped.2021.662165
- Squires J, Bricker D. Ages & Stages Questionnaires®, Third Edition (ASQ®-3): A
   Parent-Completed Child Monitoring System. Baltimore: Paul H. Brookes Publishing Co.,
   Inc; 2009.
- 572 21. Squires J, Bricker D, Potter L. Revision of a parent-completed development screening
   573 tool: Ages and Stages Questionnaires. J Pediatr Psychol. 1997;22(3):313-328.
- 574 22. Squires J, Twombly E, Bricker D, L P. Ages & Stages Questionnaires®, Third Edition
   575 (ASQ®-3): Technical Report. Baltimore: Paul H. Brookes Publishing Co., Inc; 2009.
- S76 23. Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation
  S77 of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F).
  S78 Pediatrics. 2014;133(1):37-45.
- 579 24. Achenbach TM and Rescorla LA. Manual for the ASEBA school-age forms & profiles: an
  580 integrated system of multi-informant assessment. Burlington: University of Vermont,
  581 Research Center for Children, Youth & Families; 2001.
- 58225. Alpern GD. Developmental Profile 4 (DP-4). WPS. <a href="https://www.wpspublish.com/dp-4-developmental-profile-4.html">https://www.wpspublish.com/dp-4-</a>583developmental-profile-4.htmlAccessed March 9, 2023.
- 584 26. Bayley N and Aylward GP (2019). Bayley Scales of Infant and Toddler Development (4<sup>th</sup>
   585 Ed) technical manual. Bloomington, MN: NCS Pearson.
- 586 27. Elliott CD. Manual for the Differential Ability Scales, Second Edition. San Antonio, TX:
   587 Harcourt Assessment; 2007.

- 588 28. Ghandour RM. Jones JR. Lebrun-Harris LA. et al. The design and implementation of the 589 2016 National Survey of Children's Health. Matern Child Health J 2018; 22(8):1093-1102. 590
- 591 29. Sadeh A. A brief screening questionnaire for infant sleep problems: validation and 592 findings of an internet sample. Pediatrics 2004; 113(6): e570-7.
- 593 30. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long 594 COVID in non-hospitalized adults. Nature Medicine 2022; 28:1706-1714.
- 595 31. Saadedine M, El Sabeh M, Borahay MA, Daoud G. The influence of COVID-19 infection-596 associated immune response on the female reproductive system. Biology of 597 Reproduction 2023; 108(2):172-182.
- 598 32. Edlow AG, Castro VM, Shook LL, Kaimal AJ, Perlis RH. Neurodevelopmental outcomes 599 at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy. 600 JAMA Netw Open 2022; 5(6):e2215787.
- 601 33. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic 602 Disparities. JAMA 2020;323(24):2466-2467.
- 603 34. Burris HH, Mullin AM, Dhudasia MB, et al. Neighborhood Characteristics and Racial 604 Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 605 Seropositivity in Pregnancy. Obstet Gynecol 2022;139(6):1018-1026.
- 606
- 607
- 608
- 609
- 610

		Time Point after index date															
eCRF	Baseline	3m	6m	9m	12m	15m	18m	21m	24m	27m	30m	33m	36m	39m	42m	45m	48m
Enrollment	•																
Tier 1-2 Consent	•																
Identity	•																
Visit	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•	•
Comorbidities	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
COVID Treatment*	•																
Medications																	
Change in Medications		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Demographics	•																
PASC Symptoms	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Vaccination Status	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Social Determinants of Health	•																
Social Determinants Follow-up		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Alcohol/Tobacco	•																
Alcohol/Tobacco Follow-up		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Disability	•																
Pregnancy	•																
Pregnancy Follow-up		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
Tier 1 office visit	•		•		•				•				•				•
Biospecimens	•	•	•		•				•				•				•
Lab Results	•	•	•		•				•				•				•
Tier 2/Tier 3 Tests			-	-	-	_				-	-	-	_	_	_		_

\* COVID Treatment not collected on people without infection

#### Legend

Completed by research coordinator
 Completed by participant
 Completed by research coordinator with review/validation by participant

# Figure 1



# Figure 2



# Figure 3